SC 13G: Avalo Therapeutics, Inc.

AI Summary

SC 13G filing by Avalo Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• emerald13g.htm (SC 13G) — 146KB
• image2.jpg (GRAPHIC) — 40KB
• image3.jpg (GRAPHIC) — 32KB
• 0001123292-24-000115.txt ( ) — 246KB

(a)

Item 1(a) Name of Issuer : Avalo Therapeutics, Inc. (the "Issuer")

(b)

Item 1(b) Address of Issuer's Principal Executive Offices : 540 Gaither Road, Suite 400, Rockville, Maryland 20850

(a)

Item 2(a) Name of Person Filing : This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons": (i) Emerald Bioventures, LLC (ii) Timothy Opler The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b) Address of Principal Business Office or, if none, Residence : c/o Emerald Bioventures, LLC 555 Madison Avenue, Room 11D New York, NY 10022

(c)

Item 2(c) Citizenship : (i) Emerald Bioventures, LLC: Delaware (place of organization) (ii) Timothy Opler: United States (place of residence)

(d)

Item 2(d) Title of Class of Securities : Common Stock, par value $0.001 per share

(e)

Item 2(e) CUSIP No. : 05338F306 Item 3 If this statement is filed pursuant to 240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a : (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4 Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) – (c) Reporting Person Amount beneficially owned (1) Percent of class (2) Sole power to vote or to direct the vote: Shared power to vote or to direct the vote: Sole power to dispose or to direct the disposition of: Shared power to dispose or to direct the disposition of: Emerald Bioventures, LLC 58,346 5.6% -0- 58,346 -0- 58,346 Timothy Opler 58,346 5.6% -0- 58,346 -0- 58,346 (1) Represents 58,346 shares of Common Stock beneficially owned and held by Emerald Bioventures, LLC. Timothy

View Full Filing

View this SC 13G filing on SEC EDGAR